Role of transcription factor FOXA1 in non‑small cell lung cancer

Li,Jia; Zhang,Shirong; Zhu,Lucheng; Ma,Shenglin

doi:10.3892/mmr.2017.7885

Role of transcription factor FOXA1 in non‑small cell lung cancer

Authors:
- Jia Li
- Shirong Zhang
- Lucheng Zhu
- Shenglin Ma
View Affiliations

Affiliations: Department of Oncology, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou, Zhejiang 310006, P.R. China, Center for Translational Medicine, Hangzhou First People's Hospital, Nanjing Medical University, Hangzhou, Zhejiang 310006, P.R. China
Published online on: October 26, 2017 https://doi.org/10.3892/mmr.2017.7885
Pages: 509-521

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In our previous study, stable subpopulations of the A549 lung cancer cell line with high/low invasive potential (H/L‑INV) were obtained. In the present study, microarray analysis of the H/L‑INV A549 subpopulations was performed to evaluate genes associated with high invasiveness. Forkhead box protein A1 (FOXA1) was selected for further investigation. The expression levels of FOXA1 in the primary lesion and metastatic lymph nodes were assessed using reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) analysis. In addition, the mRNA and protein expression levels of FOXA1 were examined in H‑INV A549 cells transfected with a specific FOXA1 small interfering RNA (siRNA), and the role of FOXA1 in the proliferation, invasion and metastasis of non‑small cell lung cancer (NSCLC) cells was evaluated. FOXA1 was overexpressed in metastatic lymph nodes, compared with its expression in NSCLC primary tumours. The results of western blot and RT‑qPCR analyses confirmed that FOXA1 siRNA transfection led to a decrease in the expression of FOXA1 in H‑INV A549 cells. FOXA1 siRNA transfection caused G0/G1 phase cell cycle arrest, and also reduced the invasion, migration and proliferation abilities of the H‑INV A549 cells. In conclusion, the results of the present study suggested that FOXA1 is a potential oncogene in NSCLC; therefore, specific interference of the expression of FOXA1 may represent a novel approach for the treatment of NSCLC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Zhang S, Wu K, Feng J, Wu Z, Deng Q, Guo C, Xia B, Zhang J, Huang H, Zhu L, et al: Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells. Oncotarget. 7:68768–68780. 2016. View Article : Google Scholar : PubMed/NCBI
3	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) methods. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
4	Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 12:6243–6249. 2006. View Article : Google Scholar
5	Omuro AM, Kris MG, Miller VA, Franceschi E, Shah N, Milton DT and Abrey LE: High incidence of disease recurrence in the brain and leptomeninges in patients with non-small cell lung carcinoma after response to gefitinib. Cancer. 103:2344–2348. 2005. View Article : Google Scholar : PubMed/NCBI
6	Lee YJ, Choi HJ, Kim SK, Chang J, Moon JW, Park IK, Kim JH and Cho BC: Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with non small-cell lung cancer. Cancer. 116:1336–1343. 2010. View Article : Google Scholar : PubMed/NCBI
7	Cirillo LA and Zaret KS: An early developmental transcription factor complex that is more stable on nucleosome core particles than on free DNA. Mol Cell. 4:961–969. 1999. View Article : Google Scholar : PubMed/NCBI
8	Zaret K: Developmental competence of the gut endoderm: Genetic potentiation by GATA and HNF3/fork head proteins. Dev Biol. 209:1–10. 1999. View Article : Google Scholar : PubMed/NCBI
9	Cirillo LA, Lin FR, Cuesta I, Friedman D, Jarnik M and Zaret KS: Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol Cell. 9:279–289. 2002. View Article : Google Scholar : PubMed/NCBI
10	Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, Eeckhoute J, Shao W, Hestermann EV, Geistlinger TR, et al: Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell. 122:33–43. 2005. View Article : Google Scholar : PubMed/NCBI
11	Laganiere J, Deblois G, Lefebvre C, Bataille AR, Robert F and Giguere V: From the cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci USA. 102:11651–11656. 2005. View Article : Google Scholar : PubMed/NCBI
12	Albergaria A, Paredes J, Sousa B, Milanezi F, Carneiro V, Bastos J, Costa S, Vieira D, Lopes N, Lam EW, et al: Expression of FOXA1 and GATA-3 in breast cancer: The prognostic significance in hormone receptor-negative tumors. Breast Cancer Res. 11:R402009. View Article : Google Scholar : PubMed/NCBI
13	Abe Y, Ijichi N, Ikeda K, Kayano H, Horie-Inoue K, Takeda S and Inoue S: Forkhead box transcription factor, forkhead box A1, shows negative association with lymph nodes status in endometrial cancer, and represses cell proliferation and migration of endometrial cancer cells. Cancer Sci. 103:806–812. 2012. View Article : Google Scholar : PubMed/NCBI
14	Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A, Sankila A, Turunen JP, Lundin M, Konsti J, et al: Dual role of FOXA1 in androgen receptor binding to chromatin, androgen signaling and prostate cancer. EMBO J. 30:3962–3976. 2011. View Article : Google Scholar : PubMed/NCBI
15	Song Y, Washington MK and Crawford HC: Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res. 70:2115–2125. 2010. View Article : Google Scholar : PubMed/NCBI
16	Lin L, Miller CT, Contreras JI, Prescott MS, Dagenais SL, Wu R, Yee J, Orringer MB, Misek DE, Hanash SM, et al: The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. Cancer Res. 62:5273–5279. 2002.PubMed/NCBI
17	Ma W, Jiang J, Li M, Wang H, Zhang H, He X, Huang L and Zhou Q: The clinical significance of forkhead box protein A1 and its role in colorectal cancer. Mol Med Rep. 14:2625–2631. 2016. View Article : Google Scholar : PubMed/NCBI
18	Nucera C, Eeckhoute J, Finn S, Carroll JS, Ligon AH, Priolo C, Fadda G, Toner M, Sheils O, Attard M, et al: FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin Cancer Res. 15:3680–3689. 2009. View Article : Google Scholar : PubMed/NCBI
19	Deutsch L, Wrage M, Koops S, Glatzel M, Uzunoglu FG, Kutup A, Hinsch A, Sauter G, Izbicki JR, Pantel K and Wikman H: Opposite roles of FOXA1 and NKX2-1 in lung cancer progression. Gene Chromosome Canc. 51:618–629. 2012. View Article : Google Scholar
20	Wang H, Meyer CA, Fei T, Wang G, Zhang F and Liu XS: A systematic approach identifies FOXA1 as a key factor in the loss of epithelial traits during the epithelial-to-mesenchymal transition in lung cancer. BMC Genomics. 14:6802013. View Article : Google Scholar : PubMed/NCBI
21	Zhu X, Li D, Yu F, Jia C, Xie J, Ma Y, Fan S, Cai H, Luo Q, Lv Z and Fan L: miR-194 inhibits the proliferation, invasion, migration, and enhances the chemosensitivity of non-small cell lung cancer cells by targeting forkhead box A1 protein. Oncotarget. 7:13139–13152. 2016. View Article : Google Scholar : PubMed/NCBI
22	Wang R, Shi Y, Chen L, Jiang Y, Mao C, Yan B, Liu S, Shan B, Tao Y and Wang X: The ratio of FOXA1 to FOXA2 in lung adenocarcinoma is regulated by LncRNA HOTAIR and chromatin remodeling factor LSH. Sci Rep. 5:178262015. View Article : Google Scholar : PubMed/NCBI